Trials / Completed
CompletedNCT06137573
Human Mass Balance and Biotransformation Study of [14C]TNP-2198
A Clinical Study of Absorption, Metabolism and Excretion of [14C]TNP-2198 in Healthy Adult Male Participants- Human Mass Balance and Biotransformation Study of [14C]TNP-2198
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- TenNor Therapeutics (Suzhou) Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The purpose of the study is to analyze absorption, metabolism, excretion, mass balance and biotransformation after a single oral dose of \[14C\]TNP-2198 in healthy male participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]TNP-2198 | 600mg suspension containing 150μCi of \[14C\] TNP-2198 |
Timeline
- Start date
- 2022-07-12
- Primary completion
- 2022-09-01
- Completion
- 2022-09-01
- First posted
- 2023-11-18
- Last updated
- 2023-11-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06137573. Inclusion in this directory is not an endorsement.